PredictAD

Dementia causes long and oppressive suffering to patients and their relatives and imposes enormous costs on society. About 25 million people suffered from dementia in 2000. As a 4-fold increase of this number is expected by 2050, dementia is one main health issue of the next decades.

Alzheimer's disease (AD) covers 60-70% of all dementia cases. No cure for AD exists, and effective and reliable early diagnostic techniques are lacking. Early diagnosis and progress monitoring of AD is a central part of treatment once future drugs and prevention strategies become available. There is a strong indication that different biomarkers provide a reliable and early indication of AD prior to its major clinical signs. However, optimal early diagnosis requires information from a combination of different biomarkers to be used in a clinically useful way.

The objective of PredictAD is 1) to find the best combination of biomarkers for AD diagnostics from heterogeneous data (imaging, electrophysiology, molecular level, clinical tests, demographics) and 2) to develop clinically useful tools integrating the optimal biomarker results. Comprehensive biomarker discovery techniques and rigorous statistical models will be developed using the consortium's large databases. The accuracy and usability of models and tool will be clinically evaluated. The cost-effectiveness of heterogeneous data in AD diagnostic procedures will be studied.

By reaching its objectives, PredictAD provides an efficient and reliable solution for early AD diagnosis in clinical practice. The impacts on patients, their relatives and society are reduced suffering and costs. As we are living in the dawn of an era of new drugs and prevention strategies combined with increasing AD prevalence, now is the time to exploit the vast potential of information hiding in heterogeneous patient databases. PredictAD combines the best forces in Europe to solve the AD diagnostics problem, and hence strengthens EU leadership on the market.

For further information, please visit:
http://www.predictad.eu

Project co-ordinator:
Valtion teknillinen tutkimuskeskus VTT

Partners:

  • Nexstim Oy
  • Imperial College of Science, Technology and Medicine
  • Rigshospitalet
  • Kuopion yliopisto
  • Università degli Studi di Milano
  • GE Healthcare Ltd.
  • Uppsala universitet

Timetable: from 06/2008 – to 05/2011

Total cost: € 3.981.565

EC funding: € 2.891.526

Programme Acronym: FP7-ICT

Subprogramme Area: Virtual physiological human

Contract type: Collaborative project (generic)


Related news article:

Most Popular Now

NHS Lanarkshire Launches Digital pre-Ope…

NHS Lanarkshire has launched an electronic pre-operative assessment platform to support the delivery of next generation care pathways for its patients. Working with Buddy Healthcare, the hospital Board has launched "ELSIE...

ANregiomed Puts Siemens Healthineers and…

This new technology partnership kicked off September 1, 2022, marks the first time that Siemens Healthineers is collaborating with a municipal medical service provider to implement a concept it has...

Consortium to Develop Fully Implantable …

A research consortium led by the UMC Utrecht Brain Center (the Netherlands) in collaboration with Graz University of Technology (Austria), the Wyss Center for Bio and Neuroengineering (Switzerland) and CorTec...

AI Model Outperforms Clinicians in Diagn…

An artificial-intelligence (AI) model built at Mass Eye and Ear was shown to be significantly more accurate than doctors at diagnosing pediatric ear infections in the first head-to-head evaluation of...

Creating the Digital Health Workforce of…

How are trusts and health tech suppliers going to find the people they need to develop deploy and optimise critical clinical information systems in the future? Highland Marketing's advisory board...

AI Tool could Reduce Common Drug Side Ef…

Research led by the University of Exeter and Kent and Medway NHS and Social Care Partnership Trust, published in Age and Ageing, assessed a new tool designed to calculate which...

Philips Foundation and RAD-AID Internati…

Philips Foundation, with its mission to provide access to quality healthcare for 100 million people a year in underserved communities by 2030, together with Philips and RAD-AID International, today announced...

New Tool Overcomes Major Hurdle in Clini…

Harvard Medical School scientists and colleagues at Stanford University have developed an artificial intelligence (AI) diagnostic tool that can detect diseases on chest X-rays directly from natural-language descriptions contained in...

CHOP Study Explores the Use of Telemedic…

Researchers from the Epilepsy Neurogenetics Initiative (ENGIN) at Children's Hospital of Philadelphia (CHOP) found that across nearly 50,000 visits, patients continued to use telemedicine effectively even with the reopening of...

A Smartphone's Camera and Flash could He…

First, pause and take a deep breath. When we breathe in, our lungs fill with oxygen, which is distributed to our red blood cells for transportation throughout our bodies. Our bodies...